Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Editor

Personal info

View

About

Terms

Javascript disabled

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

[edit this page]

Chemical Compound Review:

zlchem 236 1H-indazole-3-carboxylic acid

Synonyms: PubChem15666, SureCN42245, CHEMBL502057, ACMC-1ATNL, AG-B-70884, ...

Galdieri, M. et al., Gebbia, V. et al., Malorni, W. et al., Ditonno, P. et al., Del Bufalo, D. et al.

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

High impact information on NSC520610

Lonidamine, a dichlorinated derivative of indazole-3-carboxylic acid, was shown to play a significant role in reversing or overcoming multidrug resistance [1].
Lonidamine (LND) is a unique antineoplastic drug derived from indazole-3-carboxylic acid which inhibits oxygen consumption and aerobic glycolysis, interfering with energy metabolism of neoplastic cells [2].
Lonidamine (LND), a dichlorinated derivative of indazole-3-carboxylic acid, has proved to exert a powerful antiproliferative effect and to impair the energy metabolism of normal and neoplastic cells [3].
Lonidamine, an antispermatogenic compound derivative of indazole-3-carboxylic acid, administered to rat Sertoli cells induced morphological changes of the cells which rapidly shrinked forming cytoplasmic projections [4].
Lonidamine (LND), a derivative of indazole-3-carboxylic acid, is thought to disrupt energy metabolism by interfering with glycolysis and to cause cell apoptosis [5].

References

Lonidamine induces apoptosis in drug-resistant cells independently of the p53 gene. Del Bufalo, D., Biroccio, A., Soddu, S., Laudonio, N., D'Angelo, C., Sacchi, A., Zupi, G. J. Clin. Invest. (1996) [Pubmed]
Cisplatin and epirubicin plus oral lonidamine as first-line treatment for metastatic breast cancer: a phase II study of the Southern Italy Oncology Group (GOIM). Gebbia, V., Borsellino, N., Testa, A., Latteri, M.A., Milia, V., Valdesi, M., Giotta, F., Gebbia, N., Colucci, G. Anticancer Drugs (1997) [Pubmed]
The cytoskeleton as a subcellular target of the antineoplastic drug lonidamine. Malorni, W., Meschini, S., Matarrese, P., Arancia, G. Anticancer Res. (1992) [Pubmed]
Morphological and biochemical effects of lonidamine on cultured Sertoli cells. Galdieri, M., Monaco, L., De Martino, C. Exp. Mol. Pathol. (1984) [Pubmed]
Clinical Evidence Supporting the Role of Lonidamine for the Treatment of BPH. Ditonno, P., Battaglia, M., Selvaggio, O., Garofalo, L., Lorusso, V., Selvaggi, F.P. Reviews in urology. (2005) [Pubmed]

Contributions to this collaborative article are from individual authors of WikiGenes or mined by the WikiGenes Data Mining Engine from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenes Open Access Licence Privacy Policy Terms of Use apsburg

The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

Editor

Share